quinazolines has been researched along with metformin in 69 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (5.80) | 29.6817 |
| 2010's | 60 (86.96) | 24.3611 |
| 2020's | 5 (7.25) | 2.80 |
| Authors | Studies |
|---|---|
| Abraham, RT; Baker, A; Berggren, MI; Ihle, NT; Kirkpatrick, DL; Paine-Murrieta, G; Powis, G; Tate, WR; Wipf, P | 1 |
| Fimognari, FL; Franco, A; Pastorelli, R; Pellegrinotti, M; Repetto, L | 1 |
| Dugi, KA; Graefe-Mody, EU; Padula, S; Ring, A; Withopf, B | 1 |
| del Barco, S; Martín-Castillo, B; Menéndez, JA; Oliveras-Ferraros, C; Vázquez-Martín, A | 1 |
| Dugi, KA; Forst, T; Friedrich, C; Graefe-Mody, U; Herbach, K; Ring, A; Uhlig-Laske, B; Woerle, HJ | 1 |
| Dugi, KA; Kubiak, R; Patel, S; Rosenstock, J; Tamminen, I; Taskinen, MR; Woerle, HJ | 1 |
| Dugi, KA; Owens, DR; Swallow, R; Woerle, HJ | 1 |
| Jermendy, G | 2 |
| Scheen, AJ | 4 |
| Derosa, G; Maffioli, P | 1 |
| Elrod, S; Harrington, C; McLaughlin-Middlekauff, J; Singh-Franco, D | 2 |
| Haak, T; Jones, R; Meinicke, T; von Eynatten, M; Weber, S; Woerle, HJ | 2 |
| Paquot, N; Scheen, AJ | 1 |
| Bhattacharya, S; Dugi, KA; Gallwitz, B; Patel, S; Rauch, T; Rosenstock, J; von Eynatten, M; Woerle, HJ | 1 |
| Komurov, K; Moss, TJ; Muller, M; Nagrath, D; Ram, PT; Seviour, EG; Tseng, JT; Yang, L | 1 |
| Deeks, ED | 1 |
| Christensen, M; Knop, FK | 1 |
| Barnett, AH; Harper, R; Patel, S; Thiemann, S; Toorawa, R; von Eynatten, M; Woerle, HJ | 1 |
| Dayekh, K; Dimitroulakos, J; Gorn-Hondermann, I; Ma, L; Niknejad, N | 1 |
| Del Prato, S; Forst, T; Gomis, R; Owens, DR; Taskinen, MR; Woerle, HJ | 1 |
| Doupis, J; Koliaki, C | 1 |
| Haak, T | 1 |
| Gallwitz, B; Rosenstock, J; Woerle, HJ | 1 |
| Bilo, HJ; Kleefstra, N; van Hateren, KJ | 1 |
| Bakris, GL; Flynn, C | 1 |
| Gong, Y; Inagaki, N; Kagimura, T; Murai, M; Patel, S; Watada, H; Woerle, HJ | 1 |
| Gong, Y; Tong, N; Woerle, HJ; Yan, S; Yang, JK; Zeng, Z; Zhang, X | 1 |
| Ciardiello, F; D'Aiuto, E; De Palma, R; De Vita, F; Della Corte, CM; Martinelli, E; Morgillo, F; Orditura, M; Sasso, FC; Troiani, T; Vitagliano, D | 1 |
| Rodrigues, AD; Shen, H; Yang, Z; Zhang, Y; Zhao, W | 1 |
| Bhattacharya, S; Durán-Garcia, S; Patel, S; Pinnetti, S; Rosenstock, J; Thiemann, S; Woerle, HJ; Yki-Järvinen, H | 1 |
| Ashinuma, H; Chiba, T; Iwama, A; Kitamura, A; Kitazono, S; Kurosu, K; Saito-Kitazono, M; Sakaida, E; Sakao, S; Sekine, I; Tada, Y; Takiguchi, Y; Tanabe, N; Tatsumi, K; Yokosuka, O | 1 |
| Chen, CY; Chen, HJ; Chiu, HC; Huang, YC; Huang, YJ; Jian, YJ; Jian, YT; Ko, JC; Lin, YW; Syu, JJ; Tseng, SC; Wo, TY | 1 |
| Scheen, AJ; Van Gaal, LF | 1 |
| Anastassiadis, E; Diessel, S; Forst, T; Löffler, A; Pfützner, A | 1 |
| Chen, H; Han, R; He, Y; Jiang, J; Li, K; Li, L; Lin, C; Liu, H; Sun, F; Wang, Y; Xiao, H; Yang, Z | 1 |
| Buschke, S; Friedrich, C; Meinicke, T; Metzmann, K; Ring, A | 1 |
| Friedrich, C; Hohl, K; Jungnik, A; Meinicke, T; Metzmann, K; Ring, A; Schnell, D; Theodor, R | 1 |
| Böhmer, FD; Kirches, E; Mawrin, C; Pachow, D; Petermann, A; Wallesch, M; Wilisch-Neumann, A | 1 |
| Bajaj, M; Gilman, R; Kempthorne-Rawson, J; Lewis-D'Agostino, D; Patel, S; Woerle, HJ | 1 |
| Johansson, S; Leese, PT; Li, Y; Lisbon, E; Martin, P; Mathews, D; Oliver, S; Read, J; Steinberg, M | 1 |
| Berrino, L; Capuano, A; Ciardiello, F; Della Corte, CM; Fasano, M; Morgillo, F; Papaccio, F; Sasso, FC | 1 |
| Cayre, A; De Wever, O; Doan, VK; Dupouy, S; Forgez, P; Gompel, A; Kouchkar, A; Liu, J; Llorca, FP; Mourra, N; Wu, Z | 1 |
| Bailes, Z; Caballero, AE; Del Prato, S; Gallwitz, B; Lewis-D'Agostino, D; Patel, S; Ross, SA; Thiemann, S; von Eynatten, M; Woerle, HJ | 1 |
| Bessler, E; Cremers, S; Du, X; Hopkins, B; Keniry, M; Lau, YK; Maurer, MA; Parsons, RE; Pires, MM; Rayannavar, V; Shaw, J; Szabolcs, M; Thomas, T | 1 |
| Broedl, UC; DeFronzo, RA; Kaste, R; Lewin, A; Liu, D; Patel, S; Woerle, HJ | 1 |
| Byrne, FM; Chapman, V; Cheetham, S; Vickers, S | 1 |
| Beeker, A; Kordes, S; Mathôt, RA; Pollak, MN; Punt, CJ; Richel, DJ; Weterman, MJ; Wilmink, JW; Zwinderman, AH | 1 |
| Cui, Y; Friedrich, C; Hohl, K; Meinicke, T; Pichereau, S; Zhao, S; Zhao, X | 1 |
| Cao, M; Chen, H; Chu, Q; Han, R; He, Y; Sun, J; Wang, D; Wang, Y; Yao, W | 1 |
| Chen, H; Han, R; He, Y; Huang, W; Li, K; Li, L; Lin, C; Lu, C; Sun, F; Wang, Y; Zhang, K | 1 |
| Choi, J; Kim, A; Kim, C; Kim, J; Lee, J | 1 |
| Peng, Z; Shi, H; Wang, J; Xie, Y | 1 |
| Ebata, T; Ishiwata, T; Iwama, A; Iwasawa, S; Koide, S; Kurimoto, R; Sekine, I; Tada, Y; Takiguchi, Y; Tatsumi, K | 1 |
| Darko, KO; Huang, Y; Peng, CY; Peng, M; Su, Q; Tao, T; Tao, X; Xu, W; Yang, X | 1 |
| Chen, HY; He, Y; Kang, J; Li, KL; Li, L; Wang, YB; Zhang, P | 1 |
| Agbor-Tarh, D; Andersson, M; Azim, HA; Bradbury, I; Cufer, T; de Azambuja, E; Di Cosimo, S; Fumagalli, D; Gralow, J; Harris, L; Keane, M; Kroep, J; Moreno-Aspitia, A; Piccart-Gebhart, M; Salman, P; Sarp, S; Simon, SD; Sonnenblick, A; Toi, M; Wolff, AC | 1 |
| Guan, JL; Haas, M; Paul, R; Wang, C; Yeo, SK | 1 |
| Chai, M; Chu, J; Crooks, GM; de Barros, SC; Doan, NB; Fu, X; Herschman, H; Huang, J; Huang, W; Jiang, M; Jiao, J; Reue, K; Vergnes, L | 1 |
| Abdulrasool, LI; Alley, SC; Dailey, B; DeChenne, S; Endres, CJ; Lee, AJ; Mayor, JG; Rustia, EL; Topletz-Erickson, AR; Walker, LN; Wise, AL | 1 |
| Hashiguchi, Y; Hosoyamada, K; Imamura, N; Kajiya, S; Kamada, T; Komorizono, Y; Koriyama, N; Shinmaki, H; Tsukasa, M; Ueyama, N | 1 |
| Cui, WF; Ge, WJ; Li, BJ; Li, GS; Liang, RF; Song, XM; Zhang, SF; Zhang, YY | 1 |
| Cen, X; Hou, T; Najafov, A; Peng, D; Shan, B; Sun, Q; Sun, Y; Wang, Z; Xia, H; Xie, T; Xu, X; Xue, Y; Yi, C; Zhang, M; Zhao, Q | 1 |
| Cavina, B; De Luise, M; Fornasa, A; Gasparre, G; Ghelli, A; Iommarini, L; Iorio, M; Kurelac, I; Lama, E; Miglietta, S; Musiani, F; Nasiri, HR; Porcelli, AM; Sollazzo, M; Traversa, D | 1 |
14 review(s) available for quinazolines and metformin
| Article | Year |
|---|---|
mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Metformin; Models, Biological; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases | 2009 |
[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Metformin; Nitriles; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Tablets; Treatment Outcome; Triazoles; Vildagliptin | 2011 |
Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).
Topics: Area Under Curve; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Glyburide; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Pioglitazone; Purines; Quinazolines; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain | 2012 |
Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Purines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Vildagliptin | 2012 |
The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Topics: Aged; Biomarkers; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Pioglitazone; Purines; Quinazolines; Randomized Controlled Trials as Topic; Thiazolidinediones; Treatment Outcome; United States | 2012 |
Linagliptin: a review of its use in the management of type 2 diabetes mellitus.
Topics: Administration, Oral; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Linagliptin; Metformin; Purines; Quinazolines; Treatment Outcome | 2012 |
Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Purines; Quinazolines | 2012 |
Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Practice Guidelines as Topic; Purines; Quinazolines | 2012 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Evaluation; Drug Interactions; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Purines; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Efficacy and safety of Jentadueto® (linagliptin plus metformin).
Topics: Animals; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Purines; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
[Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Interactions; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Purines; Quinazolines | 2013 |
25 trial(s) available for quinazolines and metformin
| Article | Year |
|---|---|
Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
Topics: Adult; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Young Adult | 2009 |
Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome | 2010 |
Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Young Adult | 2011 |
Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds; Treatment Outcome; Young Adult | 2011 |
Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome | 2012 |
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Research Design; Sulfonylurea Compounds; Treatment Failure; Treatment Outcome | 2012 |
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds; Treatment Outcome | 2012 |
Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes.
Topics: Asian People; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Treatment Outcome | 2013 |
Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.
Topics: Aged; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Placebos; Purines; Quinazolines; Sulfonylurea Compounds | 2013 |
Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Linagliptin; Male; Metformin; Middle Aged; Pioglitazone; Purines; Quinazolines; Retrospective Studies; Thiazolidinediones; Treatment Outcome | 2013 |
Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome | 2013 |
Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Topics: Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Linagliptin; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Postprandial Period; Proinsulin; Purines; Quinazolines; Risk Factors; Sulfonylurea Compounds | 2014 |
Linagliptin fixed-dose combination with metformin is bioequivalent to co-administration of linagliptin and metformin as individual tablets.
Topics: Adult; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Prospective Studies; Purines; Quinazolines; Tablets; Therapeutic Equivalency | 2014 |
Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials.
Topics: Adult; Area Under Curve; Biological Availability; Cross-Over Studies; Drug Combinations; Female; Food-Drug Interactions; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Solubility; Tablets | 2014 |
Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Pioglitazone; Purines; Quinazolines; Thiazolidinediones; Treatment Failure; Treatment Outcome; Weight Gain | 2014 |
Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.
Topics: Adolescent; Adult; Area Under Curve; Digoxin; Drug Interactions; Female; Humans; Male; Metformin; Midazolam; Middle Aged; Omeprazole; Piperidines; Quinazolines; Ranitidine; Young Adult | 2014 |
A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Protocols; Disease-Free Survival; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Quinazolines; Research Design; Treatment Outcome; Young Adult | 2015 |
Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; International Cooperation; Linagliptin; Metformin; Purines; Quinazolines; Treatment Outcome | 2015 |
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome; Weight Loss | 2015 |
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
Topics: Academic Medical Centers; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Metformin; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Netherlands; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
Relative bioavailability study of linagliptin/metformin tablets in healthy Chinese subjects.
Topics: Administration, Oral; Adult; Area Under Curve; Asian People; Biological Availability; China; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Female; Half-Life; Healthy Volunteers; Humans; Hypoglycemic Agents; Linagliptin; Male; Metabolic Clearance Rate; Metformin; Purines; Quinazolines; Tablets; Young Adult | 2015 |
A Multicenter Double-blind Phase II Study of Metformin With Gefitinib as First-line Therapy of Locally Advanced Non-Small-cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Double-Blind Method; Female; Gefitinib; Humans; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Quinazolines; Research Design; Survival Analysis; Young Adult | 2017 |
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.
Topics: Antineoplastic Agents; Breast Neoplasms; Diabetes Mellitus; Disease-Free Survival; Female; Humans; Hypoglycemic Agents; Insulin; Lapatinib; Metformin; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2017 |
Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Biological Transport; Creatinine; Cross-Over Studies; Dogs; Female; Glomerular Filtration Rate; Healthy Volunteers; HEK293 Cells; Humans; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Male; Metformin; Middle Aged; Organic Cation Transport Proteins; Organic Cation Transporter 2; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Young Adult | 2021 |
Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Non-alcoholic Fatty Liver Disease; Purines; Quinazolines; Treatment Outcome | 2021 |
30 other study(ies) available for quinazolines and metformin
| Article | Year |
|---|---|
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Glucose Tolerance Test; Gonanes; Humans; Hyperglycemia; Hypoglycemic Agents; Lung Neoplasms; Male; Metformin; Mice; Mice, SCID; Neutrophils; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pioglitazone; Quinazolines; Thiazolidinediones; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer.
Topics: Acidosis, Lactic; Adenocarcinoma; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Metformin; Quinazolines | 2009 |
Gliptin versus a sulphonylurea as add-on to metformin.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Purines; Quinazolines; Sulfonylurea Compounds | 2012 |
The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression Profiling; Genomics; Glucose; Humans; Hypoglycemic Agents; Lapatinib; Macrolides; Metformin; Models, Biological; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2012 |
Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Purines; Quinazolines; Sulfonylurea Compounds | 2012 |
Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Drug Synergism; Fibroblasts; Gefitinib; Gene Deletion; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lovastatin; Metformin; Mice; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction | 2012 |
Response letter to D. Singh-franco et al.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Metformin; Purines; Quinazolines; Thiazolidinediones | 2012 |
Response letter. Effects of linagliptin.
Topics: Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Postprandial Period; Purines; Quinazolines; Respiratory System; Weight Gain; Weight Loss | 2012 |
Preregistration of study design and non-inferiority margin - Authors' reply.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Purines; Quinazolines; Sulfonylurea Compounds | 2013 |
Preregistration of study design and non-inferiority margin.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Purines; Quinazolines; Sulfonylurea Compounds | 2013 |
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Metformin; Mice; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction; Tumor Burden; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2013 |
Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance.
Topics: 1-Methyl-4-phenylpyridinium; Cell Line; Cisplatin; Creatinine; HEK293 Cells; Humans; Kidney; Metformin; Organic Cation Transport Proteins; Piperidines; Quinazolines | 2013 |
Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line.
Topics: AC133 Antigen; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; CD24 Antigen; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Glycoproteins; Humans; Hyaluronan Receptors; Hypoglycemic Agents; Lung Neoplasms; Metformin; Mice; Mice, SCID; Neoplasm Transplantation; Peptides; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvant; Drug Synergism; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lung Neoplasms; MAP Kinase Kinase 3; MAP Kinase Kinase 6; Metformin; Mutation; MutS Homolog 2 Protein; p38 Mitogen-Activated Protein Kinases; Pyridines; Quinazolines; RNA, Small Interfering; Signal Transduction; Transgenes | 2013 |
Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Interleukin-6; Kaplan-Meier Estimate; Lung Neoplasms; Metformin; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Re-evaluation of cytostatic therapies for meningiomas in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Hydroxyurea; Losartan; Meningeal Neoplasms; Meningioma; Metformin; Mifepristone; Neurofibromin 2; Promoter Regions, Genetic; Quinazolines; Radiation Tolerance; Tamoxifen; Temozolomide; Tumor Suppressor Proteins; Verapamil | 2014 |
Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; ErbB Receptors; Female; Humans; Lapatinib; MCF-7 Cells; Metformin; Middle Aged; Neoplasm Invasiveness; Neurotensin; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Neurotensin; Signal Transduction; Time Factors; Transfection; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2014 |
Metformin and erlotinib synergize to inhibit basal breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Flow Cytometry; Humans; Hypoglycemic Agents; Immunoenzyme Techniques; Metformin; Mice; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments.
Topics: Animal Feed; Animals; Behavior, Animal; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-Fat; Glial Fibrillary Acidic Protein; Hypoglycemic Agents; Insulin; Linagliptin; Male; Metformin; Microscopy, Fluorescence; Neuroglia; Neurons; Pain; Pain Management; Pain Measurement; Pioglitazone; PPAR gamma; Purines; Quinazolines; Rats; Rats, Sprague-Dawley; Thiazolidinediones | 2015 |
Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diabetes Mellitus, Type 2; Disease-Free Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway.
Topics: Animals; Antineoplastic Agents; Bleomycin; Blotting, Western; Epithelial-Mesenchymal Transition; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Lung Diseases, Interstitial; Male; Metformin; Pulmonary Fibrosis; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Transforming Growth Factor beta | 2015 |
Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Enzyme Induction; ErbB Receptors; Estradiol; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, erbB-2; Humans; Lapatinib; MCF-7 Cells; Metformin; Neoplasm Proteins; Neuregulin-1; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; RNA, Small Interfering; Signal Transduction; Tamoxifen; Tumor Stem Cell Assay | 2016 |
[Research of the influence and mechanism about metformin on the proliferation of differentiated endometrial carcinoma cells].
Topics: Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Down-Regulation; Endometrial Neoplasms; Endometrium; Female; Humans; Hypoglycemic Agents; Metformin; Mitogen-Activated Protein Kinase 3; Phosphorylation; Quinazolines; Signal Transduction; Tyrphostins | 2015 |
Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; Cell Survival; Cisplatin; Dimethyl Sulfoxide; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Indoles; Lung Neoplasms; Metformin; Mutation; Purines; Quinazolines; Transforming Growth Factor beta | 2016 |
Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; MAP Kinase Signaling System; Metformin; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Urinary Bladder Neoplasms | 2016 |
Improved efficacy of mitochondrial disrupting agents upon inhibition of autophagy in a mouse model of BRCA1-deficient breast cancer.
Topics: Animals; Autophagy; Autophagy-Related Proteins; Benzylamines; BRCA1 Protein; Cell Line, Tumor; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Intracellular Signaling Peptides and Proteins; Mammary Neoplasms, Animal; Metformin; Mice; Mitochondria; Models, Biological; Organelle Biogenesis; Oxidative Stress; Phosphorylation; Quinazolines; Substrate Specificity; TOR Serine-Threonine Kinases; Treatment Outcome | 2018 |
Stimulation of Hair Growth by Small Molecules that Activate Autophagy.
Topics: Aging; Allyl Compounds; Alopecia; AMP-Activated Protein Kinases; Animals; Autophagy; Butyrates; Cell Division; Female; Hair; Hair Follicle; Ketoglutaric Acids; Male; Metformin; Mice; Mice, Inbred C57BL; Oligomycins; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2019 |
Rutaecarpine enhances the anti-diabetic activity and hepatic distribution of metformin via up-regulation of Oct1 in diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Indole Alkaloids; Liver; Metformin; Quinazolines; Rats; Up-Regulation | 2021 |
Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Benzothiazoles; Benzylamines; Cell Line, Tumor; Chaperone-Mediated Autophagy; Disease Models, Animal; Gene Expression Regulation; HEK293 Cells; HeLa Cells; HSC70 Heat-Shock Proteins; Humans; I-kappa B Kinase; Isoenzymes; Male; MAP Kinase Kinase Kinases; Metformin; Mice; Mice, Transgenic; Neurons; Neuroprotective Agents; PC12 Cells; Phenylurea Compounds; Quinazolines; Rats; Signal Transduction | 2021 |
NDUFS3 knockout cancer cells and molecular docking reveal specificity and mode of action of anti-cancer respiratory complex I inhibitors.
Topics: Electron Transport Complex I; Humans; Metformin; Molecular Docking Simulation; NADH Dehydrogenase; Neoplasms; Quinazolines | 2022 |